Reimbursement dispute over prostate cancer drug delays patient access (medicalindependent.ie)

• HSE delays reimbursement for a prostate cancer drug pending cost-effectiveness review.
• Patient advocates call for expedited access to the therapy.
• Case highlights broader challenges in balancing innovation with budget sustainability.

"An analysis examines the conflict between HSE reimbursement processes and patient access to a prostate cancer drug, highlighting tensions in health technology assessment and innovation adoption."